Seeking Alpha
View as an RSS Feed

Joseph Krueger  

View Joseph Krueger's Articles BY TICKER:
Show Summaries  |  Hide Summaries
  • Sanofi-Aventis Seeks the Holy Grail of Insulin
    Sep. 28, 2010 SNY, BIOD, MNKD 42 Comments
  • Biodel's Linjeta Should Overcome the Usual FDA Approval Hurdles
    Sep. 15, 2010 BIOD, MNKD 148 Comments
  • Arena's Lorcaserin: Weighed Down by Qnexa and Meridia
    Sep. 6, 2010 ARNA, OREX, VVUS 115 Comments
  • Vivus, Arena and Orexigen Investors All Worried About Qnexa FDA Panel Review
    Jul. 13, 2010 OREX, VVUS, ARNA 97 Comments
  • Affymax Sell-Off: Did Investors Overreact?
    Jul. 8, 2010 AFFY 43 Comments
  • Myriad Pharmaceuticals: A Value Investor's Dream
    Jun. 21, 2010 MYRX 2 Comments
  • The Market Is Wrong About Vanda
    Jun. 21, 2010 VNDA 43 Comments
  • 4 Biotech Clearance Rack Stocks
    Jun. 14, 2010 CLDX, BIOD, MNKD 60 Comments
  • Digital Pathology Will Usher in a New Era of Personalized Medicine
    Jun. 14, 2010 MYRX, SQNM, ILMN 7 Comments
  • Why Biodel Is Breathing Easy, Part 2
    May 3, 2010 BIOD, GNBT, LLY 43 Comments
  • Why Biodel Is Breathing Easy, Part 1
    May 3, 2010 MNKD, LLY, NVO 1 Comment
  • Mannkind's Afrezza: No Real Benefits for Diabetics or Investors
    Editors' Pick  • May 2, 2010 MNKD, LLY, NVO 36 Comments
  • Mannkind's Afrezza Seems Short of Breath
    Apr. 30, 2010 NVO, PFE, LLY 76 Comments
  • CytRx: All That Glitters Could Be Gold
    Apr. 20, 2010 CYTR, NVS, BMY 7 Comments
  • Antigenics Should Emerge From Dendreon's Shadow Soon
    Apr. 13, 2010 AGEN, DNDN, BMY 40 Comments
  • Catalyst Pharmaceutical: Fast Track to Big Rewards
    Editors' Pick  • Apr. 12, 2010 SNY, CPRX, HLUKY 3 Comments
  • Rosetta Genomics: Giving Isis and Alnylam a Run for Their miRNAs?
    Apr. 8, 2010 GSK, ALNY, ISIS 23 Comments
  • Prolor Biotech: A Solution to Big Pharma’s Problems
    Jan. 28, 2010 MRK, AMGN, BYERF 8 Comments
  • The Future of Biotech: Party Like It's 1999
    Jan. 17, 2010 AMGN, BIIB, CELG 15 Comments
  • Poniard Pharmaceuticals: Oversold, Undervalued, Poised for Short Squeeze
    Jan. 11, 2010 PARD 17 Comments